| ￥4000 | |
| Z05728-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | OX40/TNFRSF4/CD134, His & Avi, Human captured on CM5 Chip via AntiHis Antibody can bind Human OX40 Ligand, hFc Tag in SPR assay (Biacore T200). Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 23.2 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 48-55 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | Tumor necrosis factor receptor superfamily, member 4 (TNFRSF4), also known as CD134 and OX40 receptor. OX40 is a secondary co-stimulatory immune checkpoint molecule, expressed after 24 to 72 hours following activation; its ligand, OX40L, is also not expressed on resting antigen presenting cells, but is following their activation. |
| Synonyms | CD134; OX40; OX40L receptor; TNFRSF4; ACT-135; Ly-70; OX40 homologue; TXGP1L; IMD16 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
